TY - JOUR
T1 - Molecular determinants of state-dependent block of voltage-gated sodium channels by pilsicainide
AU - Desaphy, J. F.
AU - Dipalma, A.
AU - Costanza, T.
AU - Bruno, C.
AU - Lentini, G.
AU - Franchini, C.
AU - George, A. L.
AU - Conte Camerino, D.
PY - 2010/7
Y1 - 2010/7
N2 - Background and purpose: Pilsicainide, an anti-arrhythmic drug used in Japan, is described as a pure sodium channel blocker. We examined the mechanisms by which it is able to block open channels, because these properties may be especially useful to reduce hyperexcitability in pathologies characterized by abnormal sodium channel opening. Experimental approach: The effects of pilsicainide on various heterologously expressed human sodium channel subtypes and mutants were investigated using the patch clamp technique. Key results: Pilsicainide exhibited tonic and use-dependent effects comparable to those of mexiletine and flecainide on hNav1.4 channels. These use-dependent effects were abolished in the mutations F1586C and Y1593C within segment 6 of domain IV, suggesting that the interaction of pilsicainide with these residues is critical for its local anaesthetic action. Its affinity constants for closed channels (KR) and channels inactivated from the closed state (KI) were high, suggesting that its use-dependent block (UDB) requires the channel to be open for it to reach a high-affinity blocking site. Accordingly, basic pH, which slightly increased the proportion of neutral drug, dramatically decreased KR and KI values. Effects of pilsicainide were similar on skeletal muscle hNav1.4, brain hNav1.1 and heart hNav1.5 channels. The myotonic R1448C and G1306E hNav1.4 mutants were more and less sensitive to pilsicainide, respectively, due to mutation-induced gating modifications. Conclusions and implications: Although therapeutic concentrations of pilsicainide may have little effect on resting and closed-state inactivated channels, it induces a strong UDB due to channel opening, rendering the drug ideally suited for inhibition of high-frequency action potential firing.
AB - Background and purpose: Pilsicainide, an anti-arrhythmic drug used in Japan, is described as a pure sodium channel blocker. We examined the mechanisms by which it is able to block open channels, because these properties may be especially useful to reduce hyperexcitability in pathologies characterized by abnormal sodium channel opening. Experimental approach: The effects of pilsicainide on various heterologously expressed human sodium channel subtypes and mutants were investigated using the patch clamp technique. Key results: Pilsicainide exhibited tonic and use-dependent effects comparable to those of mexiletine and flecainide on hNav1.4 channels. These use-dependent effects were abolished in the mutations F1586C and Y1593C within segment 6 of domain IV, suggesting that the interaction of pilsicainide with these residues is critical for its local anaesthetic action. Its affinity constants for closed channels (KR) and channels inactivated from the closed state (KI) were high, suggesting that its use-dependent block (UDB) requires the channel to be open for it to reach a high-affinity blocking site. Accordingly, basic pH, which slightly increased the proportion of neutral drug, dramatically decreased KR and KI values. Effects of pilsicainide were similar on skeletal muscle hNav1.4, brain hNav1.1 and heart hNav1.5 channels. The myotonic R1448C and G1306E hNav1.4 mutants were more and less sensitive to pilsicainide, respectively, due to mutation-induced gating modifications. Conclusions and implications: Although therapeutic concentrations of pilsicainide may have little effect on resting and closed-state inactivated channels, it induces a strong UDB due to channel opening, rendering the drug ideally suited for inhibition of high-frequency action potential firing.
KW - anti-arrhythmics
KW - hNav1.4
KW - local anaesthetic receptor
KW - open channel block
KW - pKa
KW - paramyotonia congenita
KW - pilsicainide
KW - state-dependent block
KW - voltage-gated sodium channels
UR - http://www.scopus.com/inward/record.url?scp=77954042073&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954042073&partnerID=8YFLogxK
U2 - 10.1111/j.1476-5381.2010.00816.x
DO - 10.1111/j.1476-5381.2010.00816.x
M3 - Article
C2 - 20590641
AN - SCOPUS:77954042073
SN - 0007-1188
VL - 160
SP - 1521
EP - 1533
JO - British journal of pharmacology
JF - British journal of pharmacology
IS - 6
ER -